Vetr Inc. covered Relypsa Inc (NASDAQ:RLYP), raising its target price to $31.16 today
- Updated: September 18, 2016
Displaying a price of $31.99, Relypsa Inc (NASDAQ:RLYP) traded 0.00% even on the day. With the last stock price up 57.77% from the two hundred day moving average, compared with the S&P 500 which has decreased -0.01% over the same time period. RLYP has registered a 50-day moving average of $30.31 and two hundred day average of $20.28. 0 shares of RLYP were exchanged, down from ann avg. volume of 3,362,590
Relypsa Inc (NASDAQ:RLYP) had its price target upped to $31 by Vetr Inc. in a report released 9/19/2016. The new target price indicates a potential downside of -0.03% based on the bussiness’ previous closing price.
In addition to Vetr Inc. reporting it’s stock price target, a total of 12 brokers have released a research note on the company. The consensus target stock price is $32.00 with eight analysts rating the stock a strong buy, three firms rating the company a buy, one firm rating the stock a hold, two analysts rating the company to underperform, and lastly 0 firms rating the company as sell.
Relypsa Inc has a one-year low of $10.26 and a one-year high of $32.12 . The company’s market cap is presently $0.0.
About Relypsa Inc (NASDAQ:RLYP)
Relypsa, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia. Hyperkalemia is a life threatening condition defined as abnormally elevated levels of potassium in the blood. Veltassa is a non-absorbed, potassium binding polymer. The active ingredient in Veltassa is a cross-linked polymeric bead that includes calcium as a counterion. Veltassa is a dry powder that is combined with small amounts of water prior to administration. Veltassa is packaged in single-use packets containing approximately 8.4 grams, 16.8 grams or 25.2 grams patiromer, and with a recommended starting dose of approximately 8.4 grams patiromer once daily.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.